In this Viewpoint, 2016 Lasker Award winners Ralf Bartenschlager, Charles Rice, and Michael Sofia discuss their work developing a system to study the replication of hepatitis C virus and a class of antivirals to treat the infection.
This Medical News article discusses recent efforts by the Department of Veterans Affairs to extend new hepatitis C treatments to all veterans within its health care system.
This Viewpoint calls for government support for providing direct–acting antiviral treatment to American Indian/Alaska Native population, which is disproportionately infected by hepatitis C virus.
This pilot study reports high rates of posttreatment sustained virologic response after use of combined ledipasvir and sofosbuvir among patients co-infected with hepatitis C virus genotype 1 and human immunodeficiency virus.
Kohli and coauthors review the safety, efficacy, and tolerability of current approved interferon-based regimens and oral interferon-free regimens for treating hepatitis C virus infection and provide treatment recommendations for specialists and generalists based on published evidence.
The PHOTON-1 investigators report that, after 12 or 24 weeks of treatment patients coinfected with HIV and hepatitis C virus who received an oral, interferon-free combination of sofosbuvir and ribavirin for 12 or 24 weeks had high rates of sustained virologic response.
To assess the addition of sofosbuvir to ribavirin to treat liver disease in patients with hepatitis C virus, especially among patients with unfavorable treatment characteristics—black race, genotype 1a, advanced liver fibrosis, and obesity—Osinusi and coauthors conducted a 2-part, single-center, randomized open-label trial involving 60 patients. They compared the combination treatment of weight-based or low-dose ribavirin treatment plus 400 mg/d of sofosbuvir for 24 weeks.
This Special Communication summarizes published evidence about the causes of elevated prescription drug prices in the United States and proposes policy options to mitigate the effects of high prices while preserving incentives for development and innovation.
This Viewpoint describes how a shortage of health care workers providing treatment for hepatitis C hinders access to treatment, despite progress in drug efficacy and reductions in drug costs.
This Viewpoint discusses the need to achieve consensus around management strategies for patients with hyperlipidemia when proprotein convertase subtilisin/kexin type 9 (PCSK-9) inhibitors enter the marketplace.